Infliximab paediatric crohns disease educational plan: A European, cross-sectional, multicentre evaluation

Drug Safety

Volumn 33, Issue 6, 2010, Pages 489-501

  Arana, Alejandro ^a   Allen, Sam ^b   Burkowitz, Jörg ^c   Fantoni, Valerio ^d   Ghatnekar, Ola ^e   Rico, María Teresa ^f   Vanhaverbeke, Nathalie ^g   Wentworth, Charles E ^h   Brosa, Max ⁱ   Arellano, Felix M ^a,h  

^a Risk MR Pharmacovigilance Services   (Spain)

^b PH ASSOCIATES   (United Kingdom)

^c Alpha Care GmbH   (Germany)

^d International Surveys Italy   (Italy)

^e SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^f Schering Plough   (Spain)

^g CEMKA EVAL   (France)

^h Risk Management Resources   (United States)

ⁱ Oblikue Consulting   (Spain)

Author keywords

Children; Crohns disease, management; Infliximab, therapeutic use; Risk management

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; AWARENESS; CANCER SCREENING; CROHN DISEASE; DRUG INDUSTRY; DRUG SAFETY; DRUG USE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; INFECTION; INFECTION RISK; INTERVIEW; PATIENT SAFETY; PHYSICIAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; STAFF TRAINING; STRUCTURED QUESTIONNAIRE; TUBERCULOSIS; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; DATA BASE; DRUG SURVEILLANCE PROGRAM; EUROPE; EVALUATION; HEALTH CARE QUALITY; MEDICAL EDUCATION; METHODOLOGY; MULTICENTER STUDY; PERSONNEL MANAGEMENT; PRACTICE GUIDELINE; RISK MANAGEMENT; STATISTICS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; DATABASES AS TOPIC; EDUCATION, MEDICAL; EUROPE; GASTROINTESTINAL AGENTS; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PROGRAM EVALUATION; RISK MANAGEMENT; STAFF DEVELOPMENT;

EID: 77952852168     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11532550-000000000-00000     Document Type: Article

References (32)

1. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009; 22: 403-409
2. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376
3. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005; 34: 819-836
4. Last JM. Scope and methods of prevention. In: Last JM, Wallace RB, editors. Maxcy-Rosenau-Last public health and preventive medicine. 13th ed. Stamford (CT): Apple-ton and Lange, 1992: 3-10
5. Koplan JP, on behalf of CDC members. Framework for program evaluation in public health. MMWR 1999; 48 (RR11): 1-40 [online]. Available from URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4811a1.htm [Accessed 2010 Mar 26]
6. Montgomery SM, Morris DL, Thompson NP, et al. Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort. BMJ 1998; 316: 1058-1059
7. Rubin GP, Hungin APS, Kelly PJ, et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14: 1553-1559
8. Kyle J. Crohn's disease in the northeastern and northern Isles of Scotland: an epidemiological review. Gastro-enterology 1992; 103: 392-399
9. Probert CS, Jayanthi V, Hughes AO, et al. Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire. Gut 1993; 34: 1547-1551
10. Brahme F, Lindstrom C, Wenckert A. Crohn's disease in a defined population: an epidemiological study of incidence, prevalence, mortality, and secular trends in the city of Malmo, Sweden. Gastroenterology 1975; 69: 342-351
11. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastro-enterol 2006; 12: 75-81
12. Lindberg E, Jornerot G. The incidence of Crohn's disease is not decreasing in Sweden. Scand J Gastroenterol 1991; 26: 495-500
13. Lindgren A, Wallerstedt S, Olsson R. Prevalence of Crohn's disease and simultaneous occurrence of extraintestinal complications and cancer: an epidemiologic study in adults. Scand J Gastroenterol 1996; 31: 74-78
14. Loffler A, Glados M. Data on the epidemiology of Crohn's disease in the city of Cologne. Med Klin 1993; 88: 516-519
15. Daiss W, Scheurlen M, Malchow H. Epidemiology of inflammatory bowel disease in the county of Tubingen (West Germany). Scand J Gastroenterol Suppl 1989; 170: 39-43
16. Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-1987: a six-fold increase in incidence. Scand J Gastroenterol 1992; 27: 609-614
17. Mate-Jimenez J, Munoz S, Vicent D, et al. Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. J Clin Gastroenterol 1994; 18: 27-31
18. Vucelic B, Korac B, Sentic M, et al. Epidemiology of Crohn's disease in Zagreb, Yugoslavia: a ten-year prospective study. Intl J Epidemiol 1991; 20: 216-220
19. Trallori G, Palli D, Saieva C, et al. A population-based study of inflammatory bowel disease in Florence over 15 years (1978-1992). Scand J Gastroenterol 1996; 31: 892-899 (Pubitemid 26313431)
20. Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004; 10: 404-410
21. Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemio-logy and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60
22. Gasche C, Scholmerich J, Brynskov J, et al. A simple clas-sification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15
23. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
24. Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival [published erratum appears in Gastroenterology 1999; 116: 1507]. Gastro-enterology 1998; 114: 1161-1168
25. Grossman AB, Mamula P. Crohn disease. Emedicine [on-line]. Available from URL: http://emedicine.medscape.com/article/928288-overview [Accessed 2008 Dec 11]
26. Kugathasan S. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143: 525-531
27. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastro-enterol Nutr 2009; 48: 386-388
28. European Medicines Agency. Annex C: template for EU Risk Management Plan (EU-RMP). Post-authorisation evaluation of medicines for human use. Doc. ref. EMEA/192632/2006 [online]. Available from URL: eudravigilance. emea.europa.eu/human/docs/19263206en.pdf [Accessed 2010 Mar 26]
29. Durlak JA. Why program implementation is important. J Prev Interv Community 1998; 17: 5-18
30. Schweitzer M, Asch DA. Timing payments to subjects of mail surveys: cost-effectiveness and bias. J Clin Epidemiol 1995; 48: 1325-1329
31. Scott I. You can't believe all that you're told: the issue of unvalidated questionnaires. Inj Prev 1997; 3: 5-6
32. Rychetnik L, Frommer M, Hawe P, et al. Criteria for eval-uating evidence on public health interventions. J Epidemiol Community Health 2002; 56: 119-127